Literature DB >> 11269638

Antimalarial chemoprophylaxis in infants and children.

M H Kramer1, H O Lobel.   

Abstract

The evolving patterns of drug resistance in malaria parasites and changes in recommendations for malaria prevention present a challenge to physicians who advise travellers on chemoprophylaxis. Because compliance with personal protection measures is usually low, children should receive appropriate chemoprophylaxis, including breast-fed infants who are not protected through maternal chemoprophylaxis. For travel to areas where chloroquine resistance has not yet been reported (i.e. parts of Central America, the Caribbean and parts of the Middle East), chloroquine alone is sufficient for antimalarial prophylaxis. Mefloquine is the drug of choice for chemoprophylaxis in areas with chloroquine-resistant Plasmodium falciparum, and can be given to infants and young children. The combination of chloroquine and proguanil is well tolerated in children but is much less effective against drug-resistant malaria. Further research is needed to determine the best dosage regimen for antimalarial drugs used for chemoprophylaxis in children.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11269638     DOI: 10.2165/00128072-200103020-00004

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.022


  49 in total

1.  Plasmodium vivax resistance to chloroquine (R2) and mefloquine (R3) in Brazilian Amazon region.

Authors:  G Alecrim M das; W Alecrim; V Macêdo
Journal:  Rev Soc Bras Med Trop       Date:  1999 Jan-Feb       Impact factor: 1.581

2.  Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers. A randomized, double-blind, placebo-controlled trial.

Authors:  C Ohrt; T L Richie; H Widjaja; G D Shanks; J Fitriadi; D J Fryauff; J Handschin; D Tang; B Sandjaja; E Tjitra; L Hadiarso; G Watt; F S Wignall
Journal:  Ann Intern Med       Date:  1997-06-15       Impact factor: 25.391

3.  Convulsions associated with prophylactic antimalarial drugs: implications for people with epilepsy.

Authors:  D R Fish; M L Espir
Journal:  BMJ       Date:  1988 Aug 20-27

Review 4.  Drug treatment and prevention of malaria.

Authors:  N J White
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  Population pharmacokinetics of mefloquine in patients with acute falciparum malaria.

Authors:  J A Simpson; R Price; F ter Kuile; P Teja-Isavatharm; F Nosten; T Chongsuphajaisiddhi; S Looareesuwan; L Aarons; N J White
Journal:  Clin Pharmacol Ther       Date:  1999-11       Impact factor: 6.875

6.  Mefloquine therapy for Plasmodium falciparum malaria in children under 5 years of age in Malawi: in vivo/in vitro efficacy and correlation of drug concentration with parasitological outcome.

Authors:  L M Slutsker; C O Khoromana; D Payne; C R Allen; J J Wirima; D L Heymann; L Patchen; R W Steketee
Journal:  Bull World Health Organ       Date:  1990       Impact factor: 9.408

7.  Malaria incidence and prevention among European and North American travellers to Kenya.

Authors:  H O Lobel; P A Phillips-Howard; A D Brandling-Bennett; R Steffen; C C Campbell; A Y Huong; J B Were; R Moser
Journal:  Bull World Health Organ       Date:  1990       Impact factor: 9.408

8.  Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa.

Authors:  R Steffen; E Fuchs; J Schildknecht; U Naef; M Funk; P Schlagenhauf; P Phillips-Howard; C Nevill; D Stürchler
Journal:  Lancet       Date:  1993-05-22       Impact factor: 79.321

9.  Malaria prophylaxis: identifying risk groups for non-compliance.

Authors:  T K Held; T Weinke; U Mansmann; M Trautmann; H D Pohle
Journal:  Q J Med       Date:  1994-01

10.  Survey of use of malaria prevention measures by Canadians visiting India.

Authors:  C C dos Santos; A Anvar; J S Keystone; K C Kain
Journal:  CMAJ       Date:  1999-01-26       Impact factor: 8.262

View more
  2 in total

1.  Inhibition of endosomal/lysosomal degradation increases the infectivity of human immunodeficiency virus.

Authors:  Brenda L Fredericksen; Bangdong L Wei; Jian Yao; Tianci Luo; J Victor Garcia
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

Review 2.  Modern malaria chemoprophylaxis.

Authors:  G Dennis Shanks; Michael D Edstein
Journal:  Drugs       Date:  2005       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.